Immunology
Technology upgrades needed to address future pandemics, GAO report says
Vaccine R&D and manufacturing face many challenges despite the success of COVID-19 vaccines. This is according to a new U.S. Government Accountability Office (GAO) report. Read More
Myxoma virus enters as an exciting preclinical cancer immunotherapy platform
A preclinical oncolytic viral vector platform under development was of interest at the recent Society for Immunotherapy of Cancer's 2021 annual meeting. OncoMyx Therapeutics' Chief Scientific Officer Leslie Sharp, PhD, spoke with ScienceBoard at the meeting. Read More
5 takeaways from SITC 2021
WASHINGTON, DC - The Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting November 10-14 was a successful gathering of research and clinical experts focused on the development of innovative cancer treatments. The ScienceBoard team was live onsite at the event. Editor in Chief Samantha Black, PhD, shared five takeaways from the meeting. Read More
Innovation and safety remain key amid shifting pandemic-impacted clinical trial protocols
WASHINGTON, DC - During the pandemic, clinical trial execution for cancer therapies has been challenging, said Dr. Samit Hirawat, chief medical officer at Bristol Myers Squibb, at the Society for Immunotherapy of Cancer's 2021 annual meeting. Despite the challenges presented by the pandemic, Hirawat noted that stakeholders held patient safety and innovation as key priorities. Hirawat spoke with ScienceBoard onsite at the meeting. Read More
Why one industry veteran launched a new cancer immunotherapy company
WASHINGTON, DC - Raphaël Ognar spoke with ScienceBoard onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting about the launch of NKILT Therapeutics. Read More
Where is the immunotherapy field headed after COVID-19?
WASHINGTON, DC - Best known for his contributions to the Moderna COVID-19 vaccine, former Moderna chief medical officer, Dr. Tal Zaks, PhD, chaired a session on RNA vaccines at the Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting. Zaks shared his perspectives and hopeful outlook with ScienceBoard at the meeting. Read More
Is the accelerated approval process working for cancer immunotherapies?
WASHINGTON, DC - Leveraging years of experience, Dr. Alessandra Cesano, PhD, who serves on the board of directors of the Society for Immunotherapy of Cancer (SITC), chaired a panel discussion on the accelerated approval process for cancer immunotherapies at the organization’s 2021 annual meeting. Cesano spoke with ScienceBoard at the meeting. Read More
Researchers dig into how myeloid cells contribute to killing cancer
WASHINGTON, DC - Dr. Miriam Merad, PhD, director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai is working on characterizing myeloid cells in cancer patients. Merad spoke with ScienceBoard at the Society for Immunotherapy of Cancer's 2021 annual meeting. Read More
New neoadjuvant platform helps inform combo immunotherapy selection for cancers
WASHINGTON, DC - In order to address some of the major challenges facing the immuno-oncology field, Dr. Tom Marron, PhD, has developed a platform to help researchers decide which drugs or combination of drugs to advance toward late-stage clinical trials. Marron spoke with ScienceBoard Editor in Chief, Samantha Black, PhD, onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting. Read More
$2.7B oncology cell and gene therapy market projected for 2021
The global market for oncology cell and gene therapies reached $1.6 million in 2020 and is expected to reach $2.744 billion in 2021, according to a recent article in Cell and Gene Therapy Business Outlook, a sister subscription-based publication of ScienceBoard.net. Read More
Conferences
SLAS2022 International Conference & Exhibition
February 5-9
Boston, Massachusetts United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter